BCL2L13 and myeloid sarcoma: The eQTL rs2587100 drives increased expression of BCL2L13 in MS patients [6] (Additional file 1: Table S11) and aligns with our microRNA gain/loss experiment which shows that the risk allele is under less regulation than the C allele.